术前钆塞酸增强MRI评估微血管侵犯风险预测米兰标准内单发肝细胞癌肝移植后结局
研究纳入两个三级转诊中心2008至2017年间80例以肝移植为首治的单发肝细胞癌患者,用术前MVI风险模型分为低危64例和高危16例,高危组肝移植后无复发生存率在1年、3年和5年均显著低于低危组,多变量分析显示MVI高危是RFS差的唯一显著因素。
要点
- 术前MVI风险模型可将米兰标准内单发HCC分为低危(64例)和高危(16例),两组病理MVI发生率有显著差异。
- MVI高危组肝移植后1年、3年、5年无复发生存率均显著低于低危组(1年75.0% vs 96.9%,P=0.048)。
- 多变量分析显示MVI高危是RFS差的唯一显著因素(P=0.016),肿瘤复发峰值在肝移植后20个月。
核心结论
- MVI高危的HCC患者肝移植后RFS显著低于低危患者;该模型可在米兰标准之外辅助筛选适合直接肝移植的候选者,尤其当存在替代治疗方案时。
研究设计与样本
- 两中心回顾性研究,纳入2008至2017年间以肝移植为首治的单发HCC患者80例(平均年龄51.8岁±7.5,男65例),使用术前MVI风险模型分为低危64例和高危16例,比较两组RFS并做多变量Cox回归分析。
诊断标准与关键数值
- 术前MVI风险模型将患者分为低危组(n=64)和高危组(n=16),两组病理MVI发生率有显著差异(原文未报告具体数值与P值)。
- MVI低危组肝移植后1年、3年、5年RFS率分别为96.9%(95%CI 92.7-100%)、95.3%(90.3-100%)、95.3%(90.3-100%)。
- MVI高危组肝移植后1年、3年、5年RFS率分别为75.0%(95%CI 56.5-99.5%)、62.5%(42.8-91.4%)、62.5%(42.8-91.4%)。
临床应用与阅片要点
- 对米兰标准内拟直接肝移植的单发HCC患者,术前可用MVI风险模型评估MVI高危与否以辅助候选者选择。
- MVI高危组1年、3年、5年RFS均显著低于低危组(P分别为0.048、0.008、0.008),提示高危患者移植后复发风险更高。
- 多变量分析显示MVI高危是RFS差的唯一显著因素(P=0.016),作者认为该模型可在有替代治疗选择时辅助米兰标准之外的候选者筛选。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare therapeutic outcomes after liver transplantation (LT) between hepatocellular carcinomas (HCC) with low and high risk for microvascular invasion (MVI) within the Milan criteria evaluated preoperatively.
METHODS: Eighty patients with a single HCC who underwent LT as the initial therapy between 2008 and 2017 were included from two tertiary referral medical centers in a HBV-predominant population. A preoperative MVI-risk model was used to identify low- and high-risk patients. Recurrence-free survival (RFS) after LT between the two risk groups was compared using Kaplan-Meier curves with the log-rank test. Prognostic factors for RFS were identified using a multivariable Cox hazard regression analysis.
RESULTS: Eighty patients were included (mean age, 51.8 years +/- 7.5 [standard deviation], 65 men). Patients were divided into low-risk (n = 64) and high-risk (n = 16) groups for MVI. The RFS rates after LT were significantly lower in the MVI high-risk group compared to the low-risk group at 1 year (75.0% [95% CI: 56.5-99.5%] vs. 96.9% [92.7-100%], p = 0.048), 3 years (62.5% [42.8-91.4%] vs. 95.3% [90.3-100%], p = 0.008), and 5 years (62.5% [42.8-91.4%] vs. and 95.3% [90.3-100%], p = 0.008). In addition, multivariable analysis showed that MVI high risk was the only significant factor for poor RFS (p = 0.016).
CONCLUSION: HCC patients with a high risk of MVI showed significantly lower RFS after LT than those without. This model could aid in selecting optimal candidates in addition to the Milan criteria when considering upfront LT for patients with HCC if alternative treatment options are available.
CLINICAL RELEVANCE STATEMENT: High risk for microvascular invasion (MVI) in hepatocellular carcinoma patients lowered recurrence-free survival after liver transplantation, despite meeting the Milan criteria. Identifying MVI risk could aid candidate selection for upfront liver transplantation, particularly if alternative treatments are available.
KEY POINTS: • A predictive model-derived microvascular invasion (MVI) high- and low-risk groups had a significant difference in the incidence of MVI on pathology. • Recurrence-free survival after liver transplantation (LT) for single hepatocellular carcinoma (HCC) within the Milan criteria was significantly different between the MVI high- and low-risk groups. • The peak incidence of tumor recurrence was 20 months after liver transplantation, probably indicating that HCC with high risk for MVI had a high risk of early (≤ 2 years) tumor recurrence.
引用
- Cha DI, Kang TW, Jeong WK, et al. Preoperative assessment of microvascular invasion risk using gadoxetate-enhanced MRI for predicting outcomes after liver transplantation for single hepatocellular carcinoma within the Milan criteria. Eur Radiol. 2023. PMID: 37505248. doi:10.1007/s00330-023-09936-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。